Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Amyotrophic Lateral Sclerosis (ALS)
- Parkinson Disease (PD)
- Alzheimer Disease (AD)
- Multiple Sclerosis (MS)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Ashvattha Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- May 2, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCSF · San Francisco, CA
- Stanford University · Stanford, CA
Florida · 1
- Mayo Clinic Jacksonville · Jacksonville, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.